# Livestock genetic engineering and precision breeding Gene editing and genomic selection are converging on livestock breeding — from FDA-cleared heat-tolerant cattle and disease-resistant pigs to India's first gene-edited sheep. Source: https://en.bioecon.ru/technology/livestock-gene-editing-precision-breeding/ Updated: 2026-08-18 ## Overview and value chain Markers: [EC: FDA Guidance for Industry #187 (Intentionally Altered Genomic DNA in Animals) | OECD: Agricultural biotechnology | Regulator: FDA (USA), CFIA (Canada), MARA (China)] Livestock genetic engineering combines CRISPR-Cas9 gene editing with genomic selection to accelerate traits that classical breeding reaches only after many generations. Porcine Reproductive and Respiratory Syndrome (PRRS) alone costs US pork producers an estimated $1.2 billion a year, and a single exon deletion in the CD163 receptor gene removes the virus's entry point without adding any foreign DNA. The US FDA issued its first low-risk determination for an intentionally altered genomic DNA (IGA) in cattle on March 7, 2022, covering two PRLR-edited "SLICK" lines; by 2025–2026 the same low-risk framework had cleared a heat-tolerance edit and a PRRS-resistance edit for commercial use, while Canada's food-safety regulators completed an independent review in parallel. Research groups outside the big three regulatory blocs are moving in parallel: India's first gene-edited farm animal, a myostatin-pathway-edited sheep, took a single university team roughly six years and near 400 embryo- transfer trials to confirm. Key directions of livestock genetic engineering: 1. **Disease-resistance editing (Disease-Resistance Gene Editing):** single receptor-gene deletions (CD163 for PRRS) that block viral entry rather than boosting immunity, avoiding any transgene insertion. 2. **Thermotolerance editing (Thermotolerance Gene Editing):** introducing naturally occurring heat-tolerance alleles (PRLR-SLICK) from tropically adapted cattle breeds into high-yield dairy and beef lines via CRISPR-Cas9. 3. **Genomic selection and sexed semen (Genomic Selection & Sexed Semen):** SNP-chip genotyping of animals as young as ~6 months, paired with sex-sorted semen, that raises genetic gain without altering any genome. 4. **Public-sector founder-animal programs (Public-Sector Gene Editing):** university and national-institute programs in India and China producing the first confirmed gene-edited founder animals in each country, ahead of any national commercial-approval pathway. ### Sectoral value chain ``` [trait discovery] ──> [edit design] ──> [founder production] ──> [regulatory review] │ (risk-based determination) │ ▼ [commercial herd] <─── [genomic selection] <─────────────────────────┘ ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **Trait Discovery** | mining naturally occurring resistance/tolerance alleles | **In:** breed surveys, genome sequences. **Out:** candidate allele. | | **Edit Design** | CRISPR-Cas9 construct targeting the candidate gene | **In:** guide RNA, donor template. **Out:** edit construct. | | **Founder Production** | zygote injection or SCNT to derive edited founders | **In:** oocytes, edited cells. **Out:** founder embryos. | | **Regulatory Review** | risk-based safety and food-consumption assessment | **In:** genotype/phenotype data. **Out:** low-risk determination. | | **Herd Multiplication** | genomic selection expands the edited line | **In:** SNP genotyping, semen. **Out:** commercial breeding stock. | | **Commercial Deployment** | supply-chain and processor acceptance | **In:** certified animals. **Out:** market-ready livestock. | Cross-cutting technologies of the sector: - **CRISPR-Cas9 site-directed nucleases (CRISPR-Cas9 Site-Directed Nucleases):** introduce single-base or short-exon edits that replicate existing natural alleles. - **Somatic cell nuclear transfer (Somatic Cell Nuclear Transfer):** clones edited donor cells into enucleated oocytes to derive founder animals. - **SNP-chip genomic evaluation (SNP-Chip Genomic Evaluation):** genome-wide marker panels that estimate breeding values without any gene editing. --- ## US The US holds the lead regulatory pathway: the FDA's risk-based framework for intentionally altered genomic DNA in animals has cleared both a thermotolerance and a disease-resistance edit for the food supply. ### FDA low-risk determinations, IGA guidance, genomic-selection adoption - **FDA Guidance for Industry #187:** the risk-based review track that classifies genomic alterations mirroring natural alleles as low-risk rather than requiring a full new-animal-drug approval. - **Acceligen PRLR-SLICK determination (March 7, 2022):** the first FDA low-risk clearance for a gene-edited cattle line, covering two heat-tolerant lines and their offspring. - **Genomic selection at scale:** US dairy herds routinely genotype heifers at roughly six months of age, combining SNP-chip evaluation with sexed and beef semen to raise genetic merit without any editing. --- ## CN China's activity sits at the research stage: university groups are publishing CRISPR-edited livestock embryo work, while the national biosafety framework has not yet opened a commercial-approval pathway for gene-edited farm animals. ### CRISPR dairy-cattle heat tolerance, MARA biosafety review, cloning-scale infrastructure - **Inner Mongolia Agricultural University PRLR/SCNT program:** CRISPR-Cas9 editing of a 20–150 bp region of the bovine PRLR gene, combined with somatic cell nuclear transfer, to study heat-stress resilience in dairy cow embryos. - **MARA biosafety review track:** gene-edited animal research is evaluated case-by-case; unlike the US and Canada there is no standing commercial-approval pathway yet for gene-edited livestock products. - **Large-scale cloning infrastructure:** China's existing industrial-scale cattle-cloning capacity is an adjacent production base that gene-edited lines could eventually multiply through, once a commercial pathway opens. --- ## EU The EU proper still applies its pre-2001 GMO framework to gene-edited farm animals, while the UK has moved fastest among European jurisdictions with a dedicated precision-breeding regime and an FDA-adjacent commercial approval. ### UK Precision Breeding Act, EU GMO-directive gap, swine disease-resistance R&D - **Genus plc / PIC PRRS-resistant pig program:** a CD163-exon deletion that blocks the PRRS virus's cell-entry point; approved by the FDA on April 30, 2025, and by Health Canada and the CFIA on January 23, 2026. - **UK Precision Breeding Act (2023):** enacted for plants first, with secondary legislation for precision-bred animals still pending as of 2026. - **EU Directive 2001/18 gap:** the EU-27 continues to regulate gene-edited farm animals under its original GMO directive, with no dedicated animal precision-breeding pathway yet in force. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **Acceligen** | 🇺🇸 USA | *PRLR-SLICK cattle* | FDA low-risk determination (Mar 2022); CRISPR PRLR heat-tolerance edit | Commercial | | **Genus plc / PIC** | 🇬🇧 UK | *PRRS-Resistant Pig* | CD163 exon deletion; FDA-approved Apr 2025, Health Canada/CFIA Jan 2026 | Commercial | | **Semex** | 🇨🇦 Canada | *Genomic selection & sexed-semen programs* | SNP-chip genomic evaluation, sex-sorted semen | Commercial | | **SKUAST-Kashmir** | 🇮🇳 India | *India's first gene-edited sheep* | Myostatin-pathway muscle edit; ~400 embryo-transfer trials over 6 years | Research | | **Inner Mongolia Agricultural University** | 🇨🇳 China | *CRISPR PRLR dairy-cattle embryos* | SCNT-based PRLR exon editing for heat tolerance | Research | --- ## Tech stack and innovations The stack pairs targeted gene editing with population-scale genomic evaluation. 1. **CRISPR-Cas9 intentional genomic alterations (CRISPR-Cas9 IGAs):** - edits replicate alleles that already occur naturally in some breeds rather than inserting foreign DNA. - case: the FDA classified the Acceligen PRLR edit as low-risk specifically because it mirrors the natural short-hair allele found in Criollo-derived cattle. 2. **Somatic cell nuclear transfer (Somatic Cell Nuclear Transfer):** - clones an edited donor cell's nucleus into an enucleated oocyte to derive founder gene-edited embryos. - case: SKUAST-Kashmir needed roughly 400 embryo transfers over six years to confirm a single successfully edited lamb, illustrating SCNT's low efficiency ceiling. 3. **SNP-chip genomic selection (SNP-Chip Genomic Selection):** - genome-wide marker genotyping estimates breeding values months before an animal's own performance data exists. - case: US dairy heifers are genotyped at roughly six months of age on average, ahead of any breeding decision. --- ## Value chains and production pipelines ### Industrial pipeline of an intentional genomic alteration in livestock (FDA Guidance #187) ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. Trait/allele discovery │ ───> │ 2. Edit design & delivery │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Regulatory risk review │ <─── │ 3. Founder confirmation │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. Herd multiplication │ ───> │ 6. Commercial deployment │ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: Trait/allele discovery Breed surveys identify a naturally occurring resistance or tolerance allele — the PRLR short-hair allele in Criollo cattle, or the CD163 receptor variant that blocks PRRS entry. #### Stage 2: Edit design & delivery A CRISPR-Cas9 construct is designed to reproduce the natural allele, delivered by zygote microinjection or into a donor cell line for cloning. #### Stage 3: Founder confirmation Edited embryos are gestated to term and genotyped; SKUAST-Kashmir's program needed close to 400 embryo transfers over six years to confirm one correctly edited lamb. #### Stage 4: Regulatory risk review A risk-based agency review compares the edited genome against natural variation; the FDA's first cattle determination took from initial submission to a March 7, 2022 low-risk clearance. #### Stage 5: Herd multiplication SNP-chip genomic selection and sexed semen expand the edited line into a commercial-scale herd without further editing. #### Stage 6: Commercial deployment Processor and export-market acceptance is confirmed; as of 2026 no major US milk processor had yet committed to a branded price premium for gene-edited-line milk, even after full regulatory clearance.